Gene Amplification Technologies market is projected to grow at a CAGR of 9.8% by 2033: Visiongain Reports Ltd – Yahoo Finance

Visiongain has published a new report entitled Gene Amplification Technologies 2023-2033. It includes profiles of Gene Amplification Technologies and Forecasts Global Gene Amplification Technologies Market, (COVID-19 Impact Analysis):- Market Segment by Sample Type, (Single Cell, Formalin-Fixed & Paraffin-Embedded (FFPE)) Market Segment by End-User, (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Other End-Users) Market Segment by Business Type, (Gene Amplification Kits & Reagents, Gene Amplification Instruments, Gene Amplification Services, Gene Amplification Ancillaries) Market Segment by Application, (Hybridization Application, Whole Genome Amplification, Exome Sequencing Amplification, SNP Genotyping Arrays, Array CGH) Market Segment by Technology, (PCR-based Amplification, Loop-mediated Isothermal Amplification, Nucleic Acid Sequence Based Amplification, Strand Displacement Amplification, Multiple Displacement Amplification, Other Technology) plus COVID-19 Impact Analysis and Recovery Pattern Analysis (“V”-shaped, “W”-shaped, “U”-shaped, “L”-shaped), Profiles of Leading Companies, Region and Country. 

The global gene amplification technologies market was valued at US$4,587 million in 2022 and is projected to grow at a CAGR of 9.8% during the forecast period 2023-2033.
Government Regulations, Decreasing Sequencing Costs, and the Expanding Potential of Pharmacogenomics
Government regulations, decreasing sequencing costs, and the expanding potential of pharmacogenomics have all worked together to spur scientific research. There are several fully sequenced genomes as well as public and local databases of genotypes and phenotypes. Whole-genome sequencing’s usefulness was tested in 2012, and the results showed that clinically relevant discoveries were seldom reported or given a thorough clinical interpretation. Additionally, “significant human resource requirements for comprehensive clinical interpretation… persist, and substantial ambiguity remains.” Over 100 gene variations may be connected to schizophrenia, according to 2014 research.
Download Exclusive Sample of Report
https://www.visiongain.com/report/gene-amplification-market-2023/#download_sampe_div
How has COVID-19 had a significant negative impact on the Gene Amplification Technologies Market?
The coronavirus disease 2019 (COVID-19) pandemic, which was brought on by Severe Acute Respiratory Syndrome Coronavirus 2, was addressed in part by diagnostic testing (SARS-CoV-2). Through the direct detection of viral nucleic acid or protein in respiratory tract specimens, clinicians can often identify viral respiratory infections such as SARS-CoV-2. Nucleic acid amplification assays, such as polymerase chain reactions, and fast antigen-based testing, are the two methods that are most often employed to do this. The first to be created and widely used during the COVID-19 epidemic were reverse-transcriptase PCR assays. For contact tracing, epidemiological characterisation, and public health decision-making, quick and precise diagnostic tests are essential.
Depending on the clinical presentation, laboratory tests may be carried out, as well as screenings of those who don’t exhibit any symptoms. Nucleic acid amplification tests (NAAT), which need specific tools and training and may be especially difficult in environments with low resources, are frequently used to confirm SARS-CoV-2 infection. Due to technical limitations, improper sampling of respiratory specimens, improper sample preservation, and timing of sample collection relative to infection, NAAT may produce false-negative results. Technical errors, particularly contamination during the manual real-time polymerase chain reaction (RT-PCR) procedure, may result in false-positive results.
How will this Report Benefit you?
Visiongain’s 422-page report provides 176 tables and 190 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global gene amplification technologies market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Gene Amplification Technologies. Get financial analysis of the overall market and different segments including business type, sample type, application, technologies, end-user, and company size and capture higher market share. We believe that there are strong opportunities in this fast-growing gene amplification technologies market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.
What are the Current Market Drivers?
Somatic Cell Gene Amplification in Human Malignancies Has Lately Received Substantial Research
Cancers develop as a result of mutations in a subset of genes that promote growth. It is hypothesized that thorough resequencing of cancer genomes for mutations will result in the identification of several more cancer genes because the human genome sequence is now publicly available. All dividing cells, including both healthy and malignant ones, experience somatic mutations. They might develop through exposure to exogenous or endogenous mutagens, DNA replication errors, or both. Two biological kinds of somatic mutations resulting from these diverse mechanisms are present in the genomes of cancer cells. “Driver” mutations, which offer a growth advantage to the cell in which they originate and are biologically linked to the development of cancer, have undergone positive selection as a result.
The Economics of Investing in Genomics Are Essential Because Precision Economics Are Required for Precision Medicine
The transition to precision medicine depends in large part on our ability to understand genetic data. Precision medicine has a lot of potential advantages, including more effective treatment and possibly lower population expenses. But for the genomics business to effectively advance toward precision medicine, the pharmaceutical and healthcare industries will need to make a sizable financial commitment. The precision medicine and genomics sectors may face future obstacles, according to an assessment of health economics.
Download Exclusive Sample of Report
https://www.visiongain.com/report/gene-amplification-market-2023/#download_sampe_div
Where are the Market Opportunities?
Proto-Oncogene Amplification May Cause or Contribute to the Development of Tumours as Well as Their Progression
Oncogene is a gene that can lead to cancer, as suggested by its name. Oncogenes, which might cause cancer in animals, were first discovered in viruses. It was later discovered that oncogenes can be altered versions of specific normal cellular genes known as proto-oncogenes. Apoptosis, also known as controlled or planned cell death, is regulated by intact proto-oncogenes, which serve vital roles in maintaining healthy cellular development and division. Oncogenes, or copies of proto-oncogenes that have undergone mutation, may cause uncontrolled cell proliferation and the escape from cell death, which may end in the development of cancer.
The Amplified Gene May Occasionally Serve as a Viable Target for Cancer Treatment
Gene Amplification is the increase in the copy number of a specific area on a chromosomal arm. It is common in various cancers and connected to enhanced gene overexpression. Extrachromosomal elements, repetitive units at a single locus, or random regions of the genome can all be structured using amplified DNA. Amplification may be aided by frequent chromosomal fragile spots, replication errors in DNA, or dysfunctional telomeres. Amplification is a clinically relevant diagnostic and predictive tool as well as a mechanism of acquired drug resistance.
Competitive Landscape
The major players operating in the gene amplification technologies market are 4BASEBIO AG, Abbott Laboratories, Agilent Technologies, Inc., Ambion Inc., Bayer Pharmaceutics AG, Becton Dickinson and Co., Bio-Rad Laboratories, Danaher Corporation, Illumina Inc., LGC Group, Merck KGaA, MyBioSource, Nanjing Vazyme Biotech Co., New England Biolabs, PerkinElmer Inc., Promega Corporation, Qiagen N.V., Silicon Biosystems, Takara Bio Inc., Yikang Inc.These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.
Recent Developments
7 November 2022, A collaboration between Biotheus, a biotech business based in China that specializes in creating treatments for cancer and autoimmune diseases, and Merck, a well-known scientific and technology company, was recently announced. Biotheus’ turn-around-time (TAT) for its cell line characterisation decreased from roughly 60 days to 14 days by using Merck’s Blazar Rodent Panel.
10 June 2022, The Cambridge-based life sciences company 4basebio PLC collaborated with the Universities of Alabama (“UA”) and Teesside (“TU”) on a study to find a cure for Neurofibromatosis Type 1 through the development of synthetic DNA and non-viral vectors for use in the field of cell and gene therapies and vaccines (NF1).
To access the data contained in this document please email oliver.davison@visiongain.com
Avoid missing out by staying informed – order our report now.
To find more Visiongain research reports on the Pharma sector, click on the following links:
Gene Therapy R&D Market
Single-Cell Analysis Market
Mesenchymal Stem Cells Market
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: oliver.davison@visiongain.com
About Visiongain
Visiongain is one of the fastest-growing and most innovative independent market intelligence providers around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports, which cover 10-year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets with a lot of synergies. These markets include automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customised and syndicated market research reports offer a bespoke piece of market intelligence customised to your very own business needs.
Contact:
Oliver Davison
PR at Visiongain Reports Limited
Tel: + 44 0207 336 6100
Email: oliver.davison@visiongain.com
Web: www.visiongain.com

Whitefish Mountain Resort will open for the season on December 8. However, the new chair lift 4 won't be operating as was originally planned.
The Government of Canada is committed to investing in companies that develop groundbreaking technologies and innovative solutions that benefit Canadians, especially seniors, and enable them to take care of their health as well as maintain their independence and lifestyle.
Shares of BioVie (NASDAQ: BIVI) were soaring 23.6% higher as of 11:19 a.m. ET on Thursday. The big jump appears to be the result of a delayed positive reaction by investors after the drugmaker reported results earlier this week from a phase 2 study evaluating experimental therapy NE3107. On Tuesday, BioVie's share price tumbled after the company's Monday evening announcement of results from its phase 2 study of NE3107 in treating Alzheimer's disease and Parkinson's disease.
The clinical-stage biotech that specializes in IBD therapies announced positive news regarding two trials for its lead therapy.
Veru Inc. (NASDAQ:VERU) Q4 2022 Earnings Call Transcript December 5, 2022 Veru Inc. misses on earnings expectations. Reported EPS is $-0.51 EPS, expectations were $-0.3. Operator: Good morning ladies and gentlemen, and welcome to Veru Inc.’s Investor Conference Call. All participants will be in listen-only mode. After this morning’s discussion, there will be an opportunity […]
Mirati Therapeutics' pain continued Thursday amid a series of analyst downgrades after MRTX stock lost about half of its value in three days.
Under the decision, certain children 6 months through 5 years can get the updated boosters, which target two Omicron offshoots as well as the original strain of the coronavirus.
Shares of Mirati Therapeutics (NASDAQ: MRTX) slumped more than 28% on Wednesday. On Monday, the company released early phase 2 data on Adagrasib to treat non-small cell lung cancer (NSCLC), along with Keytruda, which is sold by Merck (NYSE: MRK). On Wednesday, Mirati presented the data from its Krystal 7 and Krystal 1 trials with Adagrasib, at the 2022 ESMO Immuno-Oncology Annual Congress.
Amgen is years behind rivals in developing an obesity treatment, but the company says its experimental drug could prove superior.
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces today that the positive results of a Phase 3 clinical trial of the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in adult and adolescent patients with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, have been published in Blood,1 the peer-reviewed international medical journal of the American So
Actress Kirstie Alley died of colon cancer. Dr. Bidhan Das, a Colorectal surgeon with UTHealth Houston and UT Physicians, discusses the symptoms of colon cancer and why is it on the rise among younger patients.
The FDA's decision on Pfizer's (PFE) BLA seeking approval for RSV vaccine candidate in older adults is expected in May 2023.
Is Pfizer stock a buy after the FDA gives it a speedy review for an older adult RSV vaccine? Is PFE stock a buy right now?
Foxconn urged looser COVID restrictions in China. The founder of Foxconn Technology Group (FXCOF) reportedly wrote a letter attempting to persuade the Chinese government to relax its zero-COVID policy, saying China’s position in the global supply chain was under threat, people familiar with the matter told The Wall Street Journal. Apple (AAPL)  said last month that shipments of the iPhone 14 Pro and iPhone 14 Pro Max could be delayed because of COVID restrictions in China.
GE Aerospace is investing $14 million to convert the former Springdale Avon cosmetics headquarters into its new Service Technology Acceleration Center.
The carving was unearthed under a Turkish city.
Gilead faces some challenges. But there are several reasons to think the stock could keep the momentum going.
Mirati Therapeutics' (MRTX) preliminary data from the first-line NSCLC study showed that adagrasib plus Merck's Keytruda achieved an objective response rate of 49%.
GSK plc (NYSE: GSK) announced results from the PERLA phase 2 trial investigating Jemperli (dostarlimab) + chemotherapy versus Merck & Co Inc's (NYSE: MRK) Keytruda pembrolizumab + chemo as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). Dostarlimab plus chemotherapy achieved promising results for the primary endpoint of confirmed objective response rate (ORR) and the key secondary endpoint of median progression-free survival (mPFS). The ORR was 46% (n=56/12

source